Literature DB >> 16333441

Drotrecogin alfa (activated): the first FDA-approved treatment for severe sepsis.

Anita Marie Hosac1.   

Abstract

Entities:  

Year:  2002        PMID： 16333441      PMCID： PMC1276518          DOI： 10.1080/08998280.2002.11927844

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN： 0899-8280


× No keyword cloud information.
  8 in total

Review 1.  Clinical trials for severe sepsis. Past failures, and future hopes.

Authors:  S M Opal; A S Cross
Journal:  Infect Dis Clin North Am       Date:  1999-06       Impact factor: 5.982

2.  Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care.

Authors:  D C Angus; W T Linde-Zwirble; J Lidicker; G Clermont; J Carcillo; M R Pinsky
Journal:  Crit Care Med       Date:  2001-07       Impact factor: 7.598

Review 3.  Treating patients with severe sepsis.

Authors:  A P Wheeler; G R Bernard
Journal:  N Engl J Med       Date:  1999-01-21       Impact factor: 91.245

Review 4.  Sepsis: a new hypothesis for pathogenesis of the disease process.

Authors:  R C Bone; C J Grodzin; R A Balk
Journal:  Chest       Date:  1997-07       Impact factor: 9.410

5.  Efficacy and safety of recombinant human activated protein C for severe sepsis.

Authors:  G R Bernard; J L Vincent; P F Laterre; S P LaRosa; J F Dhainaut; A Lopez-Rodriguez; J S Steingrub; G E Garber; J D Helterbrand; E W Ely; C J Fisher
Journal:  N Engl J Med       Date:  2001-03-08       Impact factor: 91.245

Review 6.  Protein C levels as a prognostic indicator of outcome in sepsis and related diseases.

Authors:  C J Fisher; S B Yan
Journal:  Crit Care Med       Date:  2000-09       Impact factor: 7.598

Review 7.  Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine.

Authors:  R C Bone; R A Balk; F B Cerra; R P Dellinger; A M Fein; W A Knaus; R M Schein; W J Sibbald
Journal:  Chest       Date:  1992-06       Impact factor: 9.410

8.  Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis.

Authors:  C Brun-Buisson; F Doyon; J Carlet; P Dellamonica; F Gouin; A Lepoutre; J C Mercier; G Offenstadt; B Régnier
Journal:  JAMA       Date:  1995-09-27       Impact factor: 56.272
  8 in total
  3 in total

Review 1.  Immunometabolism: Another Road to Sepsis and Its Therapeutic Targeting.

Authors:  Vijay Kumar
Journal:  Inflammation       Date:  2019-06       Impact factor: 4.092

Review 2.  Damage-associated molecular patterns in trauma.

Authors:  Borna Relja; Walter Gottlieb Land
Journal:  Eur J Trauma Emerg Surg       Date:  2019-10-14       Impact factor: 3.693

Review 3.  A Review of Malaysian Herbal Plants and Their Active Constituents with Potential Therapeutic Applications in Sepsis.

Authors:  Kong Yen Liew; Md Faizul Hafiz; Yi Joong Chong; Hanis Hazeera Harith; Daud Ahmad Israf; Chau Ling Tham
Journal:  Evid Based Complement Alternat Med       Date:  2020-10-28       Impact factor: 2.629
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.